CREBBP and non-Hodgkin lymphoma: In vitro and in vivo characterization of IACS-16898 pharmacologic activity was performed in the DOHH2 non-Hodgkin lymphoma cell line, previously established to be highly sensitive to CBP/p300 inhibition38,39.